Market Access in Emerging Markets
Expert-defined terms from the Advanced Skill Certificate in Market Access for Pharmaceuticals course at LearnUNI. Free to read, free to share, paired with a professional course.
Affordability – The degree to which patients, payers, or health systems c… #
Affordability – The degree to which patients, payers, or health systems can bear the cost of a pharmaceutical product without compromising access to other essential services.
In emerging markets, affordability is often assessed against gross domestic prod… #
For example, a new oncology drug priced at US$10 000 per treatment cycle may be considered affordable in a high‑income country but unaffordable in a middle‑income nation where the average annual income is US$5 000.
Practical application #
Companies conduct *budget impact analyses* to estimate the financial effect on national health insurance schemes.
Challenges #
Limited price‑sensitivity data, volatile currency exchange rates, and divergent willingness‑to‑pay thresholds across regions.
Alignment with National Health Priorities – The process of ensuring that… #
Alignment with National Health Priorities – The process of ensuring that a pharmaceutical product’s therapeutic area matches a country’s strategic health objectives, such as reducing maternal mortality or combating infectious diseases.
An example is the inclusion of a malaria vaccine in a country’s *National Immuni… #
An example is the inclusion of a malaria vaccine in a country’s *National Immunization Programme* because malaria is a top public health priority.
Practical application #
Early engagement with ministries of health to map product benefits to priority‑setting documents.
Challenges #
Rapidly shifting policy agendas, limited public health data, and competing priorities for scarce resources.
Benefit‑Risk Assessment – A systematic evaluation of the therapeutic adva… #
Benefit‑Risk Assessment – A systematic evaluation of the therapeutic advantages of a drug relative to its potential adverse effects, used to support regulatory approval and payer decisions.
In emerging markets, regulators may place greater emphasis on *real‑world eviden… #
In emerging markets, regulators may place greater emphasis on *real‑world evidence* due to limited clinical trial data.
Practical application #
Preparing a *Benefit‑Risk Narrative* that incorporates local epidemiology and healthcare infrastructure.
Challenges #
Sparse post‑marketing surveillance systems and differing cultural perceptions of risk.
Bundled Pricing – A reimbursement model where multiple services or produc… #
g., drug, diagnostics, and monitoring) are packaged together under a single price.
For instance, a tuberculosis treatment regimen may be bundled with sputum‑monito… #
For instance, a tuberculosis treatment regimen may be bundled with sputum‑monitoring kits and patient education materials.
Practical application #
Negotiating *outcome‑based payments* that link reimbursement to treatment success rates.
Challenges #
Complex contract negotiations, data collection burdens, and alignment of incentives among diverse stakeholders.
Cost‑Effectiveness Analysis (CEA) – An economic evaluation that compares… #
Cost‑Effectiveness Analysis (CEA) – An economic evaluation that compares the relative costs and health outcomes (often expressed as cost per quality‑adjusted life year) of two or more interventions.
In many emerging markets, a CEA may be required for inclusion in public formular… #
In many emerging markets, a CEA may be required for inclusion in public formularies, with thresholds set at one to three times the national GDP per capita.
Practical application #
Using local cost data to model *budget impact* and inform price negotiations.
Challenges #
Data scarcity, methodological differences, and political pressure to adopt higher‑priced innovative therapies.
Country‑Specific Pricing Strategy – The design of a product’s price point… #
Country‑Specific Pricing Strategy – The design of a product’s price point tailored to the economic, regulatory, and competitive environment of each target market.
A manufacturer may set a lower price for a generic‑competitor‑free market while… #
A manufacturer may set a lower price for a generic‑competitor‑free market while maintaining a premium in a market with strong intellectual property protection.
Practical application #
Conducting *price elasticity* studies to forecast demand elasticity at various price levels.
Challenges #
Risk of parallel trade, regulatory caps, and maintaining price integrity across borders.
Data‑Driven Market Access – The utilization of quantitative and qualitati… #
Data‑Driven Market Access – The utilization of quantitative and qualitative data to inform access strategies, including epidemiology, health economics, and payer behavior.
An example is leveraging *electronic health records* to demonstrate the prevalen… #
An example is leveraging *electronic health records* to demonstrate the prevalence of a disease and the potential impact of a new therapy.
Practical application #
Building *evidence dossiers* that combine clinical trial results with local utilization patterns.
Challenges #
Inconsistent data standards, limited digital infrastructure, and privacy regulations.
Demand Forecasting – The projection of future product sales volume based… #
Demand Forecasting – The projection of future product sales volume based on market size, disease prevalence, competitive landscape, and pricing assumptions.
Accurate forecasts enable manufacturers to align manufacturing capacity with exp… #
Accurate forecasts enable manufacturers to align manufacturing capacity with expected uptake, avoiding stockouts or excess inventory.
Practical application #
Applying *Monte Carlo simulations* to capture uncertainty in key variables such as reimbursement rates.
Challenges #
Unpredictable policy changes, supply‑chain disruptions, and limited historical sales data.
Economic Burden of Disease – The aggregate cost to society of a particula… #
Economic Burden of Disease – The aggregate cost to society of a particular illness, encompassing direct medical expenses, indirect productivity losses, and intangible costs such as pain and suffering.
Quantifying the economic burden of diabetes in an emerging market can strengthen… #
Quantifying the economic burden of diabetes in an emerging market can strengthen the case for reimbursing a novel glucose‑lowering agent.
Practical application #
Presenting *cost‑of‑illness* data in payer dossiers to illustrate potential savings from disease control.
Challenges #
Capturing informal care costs, variations in wage data, and lack of standardized costing methodologies.
Evidence Generation Plan – A roadmap outlining the types of clinical, eco… #
Evidence Generation Plan – A roadmap outlining the types of clinical, economic, and real‑world data to be collected to support market access objectives.
A plan may include *prospective observational studies* in local hospitals to gen… #
A plan may include *prospective observational studies* in local hospitals to generate effectiveness data for a cardiovascular drug.
Practical application #
Aligning study endpoints with payer‑required outcomes such as hospitalization rates.
Challenges #
Limited research infrastructure, lengthy timelines, and funding constraints.
Formulary Placement – The inclusion of a drug on a payer’s list of approv… #
Formulary Placement – The inclusion of a drug on a payer’s list of approved medications, often tiered according to clinical value and cost considerations.
Practical application #
Conducting *comparative effectiveness* studies to demonstrate superiority over existing options.
Challenges #
Negotiating with multiple payers, navigating complex tiering criteria, and managing formulary delisting risk.
Health Technology Assessment (HTA) – A multidisciplinary process that eva… #
Health Technology Assessment (HTA) – A multidisciplinary process that evaluates the clinical efficacy, safety, cost‑effectiveness, and social impact of health technologies to inform policy decisions.
In many emerging markets, HTA agencies are newly established and may rely heavil… #
In many emerging markets, HTA agencies are newly established and may rely heavily on *international reference pricing* data.
Practical application #
Submitting *HTA dossiers* that include local epidemiology, budget impact, and patient‑reported outcomes.
Challenges #
Limited technical expertise, variable methodological standards, and political influence on assessment outcomes.
Incidence vs #
Prevalence – Epidemiological measures where incidence refers to the number of new cases within a specified period, and prevalence denotes the total number of existing cases at a point in time.
Understanding incidence is crucial for launch timing of a vaccine, whereas preva… #
Understanding incidence is crucial for launch timing of a vaccine, whereas prevalence informs the size of the treatment market for chronic conditions.
Practical application #
Using *incidence data* to model uptake curves for a newly approved therapy.
Challenges #
Under‑reporting, inconsistent case definitions, and lack of national registries.
International Reference Pricing (IRP) – A pricing methodology where a cou… #
International Reference Pricing (IRP) – A pricing methodology where a country sets the price of a drug based on the price in one or more reference countries.
For example, a middle‑income country may cap the price of a biologic at 120 % of… #
For example, a middle‑income country may cap the price of a biologic at 120 % of the average price in three high‑income reference markets.
Practical application #
Preparing *price comparison tables* to anticipate IRP outcomes during negotiations.
Challenges #
Currency fluctuations, differences in purchasing power parity, and the risk of price erosion in lower‑priced markets.
Key Opinion Leader (KOL) – An influential clinician or researcher whose e… #
Key Opinion Leader (KOL) – An influential clinician or researcher whose expertise shapes clinical practice and payer perceptions in a specific therapeutic area.
Engaging a KOL in an emerging market can provide *local credibility* for a new o… #
Engaging a KOL in an emerging market can provide *local credibility* for a new oncology drug and facilitate guideline inclusion.
Practical application #
Organizing *advisory board meetings* to gather insights on local treatment pathways.
Challenges #
Identifying unbiased KOLs, managing conflicts of interest, and ensuring regulatory compliance.
Local Health Economics (LHE) – The adaptation of health‑economic models t… #
Local Health Economics (LHE) – The adaptation of health‑economic models to reflect the cost structures, resource utilization, and willingness‑to‑pay of a specific country.
An LHE model for a hepatitis C therapy may incorporate local labor costs for nur… #
An LHE model for a hepatitis C therapy may incorporate local labor costs for nurse‑administered infusions and region‑specific drug procurement prices.
Practical application #
Using *sensitivity analyses* to test the robustness of conclusions under varying local assumptions.
Challenges #
Scarcity of granular cost data, differing health system organization, and limited access to local expertise.
Market Access Barrier – Any obstacle that impedes the entry or diffusion… #
Market Access Barrier – Any obstacle that impedes the entry or diffusion of a pharmaceutical product, such as regulatory delays, pricing restrictions, or limited reimbursement coverage.
A common barrier in emerging markets is *delayed registration* due to insufficie… #
A common barrier in emerging markets is *delayed registration* due to insufficient local clinical data.
Practical application #
Conducting *gap analyses* to identify missing evidence required for market entry.
Challenges #
Navigating heterogeneous regulatory requirements, resource‑intensive data generation, and political uncertainty.
Negotiated Pricing – A price determination process where manufacturers an… #
Negotiated Pricing – A price determination process where manufacturers and payers agree on a price based on mutual interests, often involving confidential discounts or rebates.
In many emerging economies, the final price of a new biologic is disclosed only… #
In many emerging economies, the final price of a new biologic is disclosed only to the health ministry, not publicly.
Practical application #
Structuring *performance‑linked rebates* where payment is contingent on achieving predefined health outcomes.
Challenges #
Maintaining confidentiality, measuring performance accurately, and aligning contractual terms across multiple jurisdictions.
Outcome‑Based Contract (OBC) – A reimbursement agreement that ties paymen… #
Outcome‑Based Contract (OBC) – A reimbursement agreement that ties payment to the achievement of specific clinical or economic outcomes in the real world.
An OBC for a hepatitis B vaccine may stipulate that the manufacturer refunds a p… #
An OBC for a hepatitis B vaccine may stipulate that the manufacturer refunds a portion of the price if seroconversion rates fall below a pre‑agreed threshold.
Practical application #
Developing *data collection infrastructure* to track outcomes such as hospitalization rates or disease progression.
Challenges #
Data latency, attribution of outcomes to the therapy versus other factors, and administrative burden.
Patient Access Scheme (PAS) – A program, often government‑initiated, that… #
Patient Access Scheme (PAS) – A program, often government‑initiated, that facilitates the provision of high‑cost medicines to patients who would otherwise be unable to afford them.
In some emerging markets, a PAS may provide a *tiered co‑payment* where low‑inco… #
In some emerging markets, a PAS may provide a *tiered co‑payment* where low‑income patients pay a reduced share of the drug cost.
Practical application #
Aligning *eligibility criteria* with national poverty indices to target assistance effectively.
Challenges #
Complex eligibility verification, potential for misuse, and sustainability of funding.
Pharmacoeconomics – The branch of health economics that evaluates the val… #
Pharmacoeconomics – The branch of health economics that evaluates the value of pharmaceutical products by comparing costs and outcomes.
Pharmacoeconomic studies can support *price negotiations* by demonstrating that… #
Pharmacoeconomic studies can support *price negotiations* by demonstrating that a high‑priced drug yields net savings through reduced hospital stays.
Practical application #
Conducting *cost‑utility analyses* that express results in cost per quality‑adjusted life year (QALY).
Challenges #
Translating utility measures into culturally relevant values, limited local preference data, and varying methodological standards.
Pricing Cap – A regulatory limit that restricts the maximum price a pharm… #
Pricing Cap – A regulatory limit that restricts the maximum price a pharmaceutical can charge within a jurisdiction.
A pricing cap of 150 % of the average price in three reference countries may be… #
A pricing cap of 150 % of the average price in three reference countries may be imposed on a new antiretroviral drug.
Practical application #
Modeling *price elasticity* to assess revenue impact under cap scenarios.
Challenges #
Caps may discourage launch, trigger price erosion in neighboring markets, and create incentives for parallel importation.
Reimbursement Pathway – The sequence of steps that a drug must undergo to… #
Reimbursement Pathway – The sequence of steps that a drug must undergo to obtain reimbursement status, including dossier submission, health technology assessment, and price negotiation.
In many emerging markets, a *fast‑track* reimbursement pathway may be available… #
In many emerging markets, a *fast‑track* reimbursement pathway may be available for drugs addressing unmet medical needs.
Practical application #
Preparing *submission checklists* aligned with each agency’s documentation requirements.
Challenges #
Varied timelines, frequent policy revisions, and the need for localized evidence at each step.
Risk‑Sharing Agreement (RSA) – A contractual arrangement where the financ… #
Risk‑Sharing Agreement (RSA) – A contractual arrangement where the financial risk of a drug’s performance is shared between the manufacturer and the payer.
An RSA for a chronic disease may involve a *volume‑based rebate* where the manuf… #
An RSA for a chronic disease may involve a *volume‑based rebate* where the manufacturer provides a discount after a certain number of patients are treated.
Practical application #
Defining *trigger points* and *data verification* processes to activate rebates.
Challenges #
Aligning incentives, ensuring transparent data exchange, and managing administrative complexity.
Scenario Analysis – A technique that explores the impact of different ass… #
g., price changes, policy shifts) on market access outcomes.
Scenario analysis can help a company decide whether to launch a product before o… #
Scenario analysis can help a company decide whether to launch a product before or after a national health insurance reform.
Practical application #
Using *scenario trees* to visualize potential pathways and associated probabilities.
Challenges #
Limited data to assign probabilities, need for multidisciplinary input, and difficulty communicating results to non‑technical stakeholders.
Stakeholder Mapping – The process of identifying and categorizing all par… #
Stakeholder Mapping – The process of identifying and categorizing all parties who influence or are affected by a market access strategy, including regulators, payers, clinicians, patients, and NGOs.
A thorough map may reveal that an influential patient advocacy group can acceler… #
A thorough map may reveal that an influential patient advocacy group can accelerate *policy adoption* for a rare‑disease therapy.
Practical application #
Developing *relationship matrices* that assign influence and interest scores to each stakeholder.
Challenges #
Dynamic stakeholder landscapes, hidden power structures, and resource constraints for sustained engagement.
Strategic Pricing – The deliberate setting of a product’s price to achiev… #
Strategic Pricing – The deliberate setting of a product’s price to achieve specific market objectives, such as rapid uptake, market share growth, or premium positioning.
A launch strategy may employ *penetration pricing* in a low‑income market to bui… #
A launch strategy may employ *penetration pricing* in a low‑income market to build volume before shifting to a higher price after achieving brand recognition.
Practical application #
Conducting *price‑sensitivity surveys* to gauge acceptable price ranges among payers and patients.
Challenges #
Balancing short‑term revenue loss against long‑term market establishment, and managing price perception across regions.
Therapeutic Index – The ratio between the dose that produces a therapeuti… #
Therapeutic Index – The ratio between the dose that produces a therapeutic effect and the dose that causes toxicity; a high index indicates a wide safety margin.
Drugs with a narrow therapeutic index may require *intensive monitoring* program… #
Drugs with a narrow therapeutic index may require *intensive monitoring* programs, influencing reimbursement decisions in resource‑limited settings.
Practical application #
Incorporating *monitoring costs* into budget impact models for such medicines.
Challenges #
Limited laboratory capacity, higher risk of adverse events, and additional training needs for healthcare providers.
Value‑Based Pricing (VBP) – A pricing approach that links the price of a… #
Value‑Based Pricing (VBP) – A pricing approach that links the price of a drug to the value it delivers, often measured in health outcomes or cost savings.
In a VBP model, a cardiovascular drug may be priced higher if it demonstrably re… #
In a VBP model, a cardiovascular drug may be priced higher if it demonstrably reduces the incidence of costly heart‑failure hospitalizations.
Practical application #
Calculating *incremental net benefit* to set a price that reflects the drug’s added value over standard care.
Challenges #
Agreeing on a common definition of value, measuring outcomes reliably, and negotiating acceptable price floors and ceilings.
Volume‑Based Rebate – A discount that increases with the quantity of prod… #
Volume‑Based Rebate – A discount that increases with the quantity of product purchased or dispensed, encouraging higher utilization.
A manufacturer may offer a 5 % rebate after the first 10 000 units are sold, sca… #
A manufacturer may offer a 5 % rebate after the first 10 000 units are sold, scaling up to a 15 % rebate beyond 50 000 units.
Practical application #
Embedding *rebate triggers* in supply‑chain contracts and monitoring sales data to activate discounts.
Challenges #
Forecasting volume accurately, ensuring transparent accounting, and avoiding unintended market distortions.
World Health Organization (WHO) Essential Medicines List (EML) – A curate… #
World Health Organization (WHO) Essential Medicines List (EML) – A curated list of medicines deemed essential for meeting the most important health needs of a population.
Inclusion on the WHO EML can facilitate *accelerated registration* and improve r… #
Inclusion on the WHO EML can facilitate *accelerated registration* and improve reimbursement prospects in many emerging markets.
Practical application #
Aligning clinical development programs to address *priority disease areas* identified by the WHO.
Challenges #
Limited slots on the list, rigorous evidence requirements, and competition from other candidates for the same therapeutic category.
Zero‑Sum Pricing – A pricing scenario where an increase in price for one… #
Zero‑Sum Pricing – A pricing scenario where an increase in price for one market segment must be offset by a reduction elsewhere to maintain overall revenue targets.
A company may lower the price in a low‑income country while raising it in a high… #
A company may lower the price in a low‑income country while raising it in a high‑income market to keep total profit margins stable.
Practical application #
Using *price elasticity models* to predict the revenue impact of cross‑market price shifts.
Challenges #
Managing regulatory scrutiny, avoiding accusations of price discrimination, and ensuring supply continuity.
Regulatory Pathway – The sequence of steps required to obtain marketing a… #
Regulatory Pathway – The sequence of steps required to obtain marketing authorization for a pharmaceutical product, including dossier preparation, clinical trial approval, and post‑marketing commitments.
Emerging markets may offer *fast‑track* pathways for drugs that address unmet ne… #
Emerging markets may offer *fast‑track* pathways for drugs that address unmet needs, reducing time to market but often requiring additional post‑marketing data.
Practical application #
Preparing *regulatory dossiers* that incorporate both global trial data and locally relevant safety information.
Challenges #
Varying documentation standards, limited regulatory capacity, and potential for divergent post‑approval requirements.
Health Insurance Coverage – The extent to which a national or private ins… #
Health Insurance Coverage – The extent to which a national or private insurance scheme reimburses the cost of a drug, influencing patient out‑of‑pocket expenses.
In many emerging economies, public insurance may cover only a proportion of the… #
In many emerging economies, public insurance may cover only a proportion of the cost for high‑priced biologics, leaving patients to seek *catastrophic expense* assistance.
Practical application #
Designing *co‑payment assistance programs* that complement existing insurance benefits.
Challenges #
Fragmented insurance markets, varying benefit structures, and limited data on utilization patterns.
Health Outcomes Research (HOR) – The study of the end results of health c… #
Health Outcomes Research (HOR) – The study of the end results of health care interventions, focusing on patient-centered measures such as mortality, morbidity, and quality of life.
HOR data can be pivotal in negotiating *value‑based contracts* by providing evid… #
HOR data can be pivotal in negotiating *value‑based contracts* by providing evidence of clinical benefit in routine practice.
Practical application #
Conducting *prospective cohort studies* that capture outcomes across diverse care settings.
Challenges #
Standardizing outcome measures, ensuring data completeness, and integrating findings into payer decision‑making.
Pharmacovigilance – The systematic monitoring, detection, assessment, and… #
Pharmacovigilance – The systematic monitoring, detection, assessment, and prevention of adverse effects or other drug‑related problems.
Robust pharmacovigilance systems are essential for maintaining market access, es… #
Robust pharmacovigilance systems are essential for maintaining market access, especially when local regulators require *post‑marketing safety reports*.
Practical application #
Establishing *active surveillance* programs that collect adverse event data from hospitals and clinics.
Challenges #
Limited reporting infrastructure, under‑reporting of events, and the need for rapid signal detection.
Price Elasticity of Demand – A measure of how sensitive the quantity dema… #
Price Elasticity of Demand – A measure of how sensitive the quantity demanded of a product is to changes in its price.
A high elasticity indicates that a modest price increase could lead to a substan… #
A high elasticity indicates that a modest price increase could lead to a substantial drop in sales, a key consideration for premium‑priced oncology drugs in price‑sensitive markets.
Practical application #
Applying *elasticity coefficients* in financial models to estimate revenue under different pricing scenarios.
Challenges #
Obtaining reliable elasticity estimates in markets with limited historical sales data, and accounting for non‑price factors such as brand reputation.
Reimbursement Rate – The proportion of a drug’s list price that a payer a… #
Reimbursement Rate – The proportion of a drug’s list price that a payer agrees to reimburse, often expressed as a percentage or a fixed amount.
A 70 % reimbursement rate for an anti‑malaria medication may be sufficient to ac… #
A 70 % reimbursement rate for an anti‑malaria medication may be sufficient to achieve widespread use in a national malaria control program.
Practical application #
Negotiating *step‑down reimbursement* where the rate decreases after a certain utilization threshold is met.
Challenges #
Aligning reimbursement rates with budget constraints, managing disparities between public and private payers, and ensuring transparency.
Health System Capacity – The ability of a country’s health infrastructure… #
Health System Capacity – The ability of a country’s health infrastructure, workforce, and logistics to deliver medical interventions effectively.
A drug that requires cold‑chain storage may face limited uptake in regions lacki… #
A drug that requires cold‑chain storage may face limited uptake in regions lacking reliable refrigeration, affecting market access.
Practical application #
Conducting *capacity assessments* to identify gaps and propose supportive services such as training or equipment provision.
Challenges #
Resource limitations, geographic disparities, and the need for long‑term sustainability planning.
Patient Assistance Program (PAP) – Initiatives, often sponsored by manufa… #
Patient Assistance Program (PAP) – Initiatives, often sponsored by manufacturers, that provide medicines at reduced cost or free of charge to eligible patients.
PAPs can improve adherence to high‑cost therapies for chronic diseases like HIV,… #
PAPs can improve adherence to high‑cost therapies for chronic diseases like HIV, especially where insurance coverage is incomplete.
Practical application #
Defining *eligibility criteria* based on income thresholds and disease severity.
Challenges #
Regulatory restrictions on promotional activities, monitoring for misuse, and ensuring equitable distribution.
Clinical Practice Guidelines (CPG) – Systematically developed statements… #
Clinical Practice Guidelines (CPG) – Systematically developed statements that assist clinicians and patients in making decisions about appropriate health care for specific circumstances.
Inclusion of a new drug in national CPGs often accelerates *formulary placement*… #
Inclusion of a new drug in national CPGs often accelerates *formulary placement* and reimbursement approval.
Practical application #
Engaging with guideline development committees to present *evidence summaries* and address clinical concerns.
Challenges #
Long development cycles, potential bias, and the need to update guidelines as new evidence emerges.
Managed Entry Agreement (MEA) – A contractual arrangement that allows ear… #
Managed Entry Agreement (MEA) – A contractual arrangement that allows early access to a medicine while additional data on effectiveness, safety, or cost‑effectiveness are collected.
MEAs are common for innovative therapies where long‑term outcomes are uncertain,… #
MEAs are common for innovative therapies where long‑term outcomes are uncertain, enabling payers to mitigate financial risk.
Practical application #
Defining *data collection milestones* and *performance thresholds* that trigger full reimbursement.
Challenges #
Aligning timelines between manufacturers and payers, ensuring data quality, and negotiating exit clauses.
Pharmaceutical Market Segmentation – The process of dividing a market int… #
Pharmaceutical Market Segmentation – The process of dividing a market into distinct groups of patients or payers based on characteristics such as disease stage, income level, or geographic location.
Segmenting a market for a diabetes drug may involve distinguishing between *urba… #
Segmenting a market for a diabetes drug may involve distinguishing between *urban insured* patients and *rural uninsured* populations.
Practical application #
Tailoring *communication strategies* and *pricing tiers* to each segment’s needs and purchasing power.
Challenges #
Obtaining reliable segmentation data, avoiding over‑complication, and ensuring regulatory compliance across segments.
Health Economic Modeling – The construction of mathematical models that s… #
Health Economic Modeling – The construction of mathematical models that simulate the clinical and economic outcomes of health interventions over time.
Models can be *Markov* or *decision‑tree* based, capturing disease progression,… #
Models can be *Markov* or *decision‑tree* based, capturing disease progression, treatment pathways, and cost inputs.
Practical application #
Using *software platforms* to generate scenario analyses for payer submissions.
Challenges #
Parameter uncertainty, data gaps, and the need for model validation against real‑world outcomes.
Price Transparency Initiative – Efforts by governments or industry groups… #
Price Transparency Initiative – Efforts by governments or industry groups to disclose drug pricing information to improve market efficiency and reduce disparities.
Some emerging markets have mandated that manufacturers submit *price declaration… #
Some emerging markets have mandated that manufacturers submit *price declarations* for all reimbursed products.
Practical application #
Preparing *price disclosure reports* that comply with local legislation while protecting confidential information.
Challenges #
Balancing transparency with competitive concerns, managing public expectations, and adapting to evolving regulatory requirements.
Risk Management Plan (RMP) – A detailed plan outlining the strategies to… #
Risk Management Plan (RMP) – A detailed plan outlining the strategies to identify, assess, and mitigate risks associated with a pharmaceutical product throughout its lifecycle.
RMPs are often required for new molecular entities, especially for high‑risk bio… #
RMPs are often required for new molecular entities, especially for high‑risk biologics, and can influence *reimbursement negotiations*.
Practical application #
Defining *risk minimization measures* such as prescriber training or patient monitoring protocols.
Challenges #
Implementing robust monitoring in low‑resource settings, ensuring stakeholder compliance, and updating the plan as new safety data emerge.
Strategic Partnership – Collaborative arrangements between pharmaceutical… #
g., distributors, NGOs, health ministries) to facilitate market entry and improve access.
A partnership with a national immunization program can enable rapid distribution… #
A partnership with a national immunization program can enable rapid distribution of a new vaccine across remote regions.
Practical application #
Negotiating *shared‑risk agreements* where partners co‑invest in distribution infrastructure.
Challenges #
Aligning objectives, managing cultural differences, and ensuring equitable benefit sharing.
Therapeutic Substitution – The practice of replacing a prescribed drug wi… #
Therapeutic Substitution – The practice of replacing a prescribed drug with a therapeutically equivalent alternative, often a generic, to reduce costs.
In many emerging markets, therapeutic substitution policies are enforced to prom… #
In many emerging markets, therapeutic substitution policies are enforced to promote the use of lower‑cost generics for chronic conditions.
Practical application #
Demonstrating *bioequivalence* and clinical parity to gain acceptance from prescribers and payers.
Challenges #
Perceived efficacy differences, physician resistance, and regulatory hurdles for biosimilars.
Value Dossier – A comprehensive compilation of clinical, economic, and re… #
Value Dossier – A comprehensive compilation of clinical, economic, and real‑world evidence presented to payers to justify the value proposition of a drug.
A well‑crafted value dossier for a novel antiviral may incorporate *cost‑savings… #
A well‑crafted value dossier for a novel antiviral may incorporate *cost‑savings from avoided hospitalizations* and *patient‑reported outcome improvements*.
Practical application #
Structuring the dossier with clear sections on *clinical benefit*, *economic impact*, and *implementation considerations*.
Challenges #
Tailoring content to diverse payer requirements, maintaining up‑to‑date data, and balancing depth with brevity.
Volume‑Based Pricing (VBP) – A pricing model where the unit price of a dr… #
Volume‑Based Pricing (VBP) – A pricing model where the unit price of a drug declines as the total volume purchased increases, encouraging larger orders.
VBP can be advantageous in large‑scale vaccination campaigns where high volumes… #
VBP can be advantageous in large‑scale vaccination campaigns where high volumes are anticipated.
Practical application #
Setting *price brackets* that correspond to predefined purchase thresholds.
Challenges #
Forecasting demand accurately, preventing stockpiling that could distort pricing signals, and ensuring equitable access across regions.
World Bank Income Classification – A categorization of countries based on… #
World Bank Income Classification – A categorization of countries based on gross national income per capita, used to define low‑, lower‑middle, upper‑middle, and high‑income status.
Manufacturers often align their *differential pricing* approaches with these cla… #
Manufacturers often align their *differential pricing* approaches with these classifications to comply with ethical guidelines and avoid accusations of price discrimination.
Practical application #
Mapping target markets to the appropriate income tier to set *price points* that reflect purchasing power.
Challenges #
Rapid economic shifts can reclassify countries, requiring frequent price adjustments, and the need to manage cross‑border price leakage.
Regulatory Harmonization – The process of aligning regulatory requirement… #
Regulatory Harmonization – The process of aligning regulatory requirements across multiple jurisdictions to streamline product approval.
The African Medicines Regulatory Harmonization (AMRH) initiative exemplifies eff… #
The African Medicines Regulatory Harmonization (AMRH) initiative exemplifies efforts to create a common technical dossier for multiple African nations.
Practical application #
Preparing *common technical documents* that satisfy the standards of all participating countries.
Challenges #
Divergent national legal frameworks, varying capacity among regulatory authorities, and the need for extensive stakeholder coordination.
Health Budget Impact Model (HBIM) – An analytical tool that estimates the… #
Health Budget Impact Model (HBIM) – An analytical tool that estimates the financial consequences of adopting a new therapy within a specific health budget context.
HBIMs help payers understand the *short‑term fiscal implications* of reimbursing… #
HBIMs help payers understand the *short‑term fiscal implications* of reimbursing a high‑cost oncology drug versus existing standards of care.
Practical application #
Incorporating *population uptake forecasts* and *price negotiations* into the model to present realistic budget scenarios.
Challenges #
Accurately projecting uptake, accounting for competing priorities, and communicating uncertainty to decision‑makers.
Risk‑Adjusted Discount Rate – A discount rate applied in economic evaluat… #
Risk‑Adjusted Discount Rate – A discount rate applied in economic evaluations to reflect the uncertainty and risk associated with future cash flows or health outcomes.
Higher risk‑adjusted rates may be used when evidence is limited, leading to more… #
Higher risk‑adjusted rates may be used when evidence is limited, leading to more conservative cost‑effectiveness estimates.
Practical application #
Selecting an appropriate rate based on *data robustness* and *market volatility* in emerging economies.
Challenges #
Lack of consensus on appropriate rates, sensitivity of results to discounting assumptions, and the need for transparent justification.
Pharmacy Benefit Manager (PBM) – An intermediary that administers prescri… #
Pharmacy Benefit Manager (PBM) – An intermediary that administers prescription drug programs on behalf of insurers, influencing formulary design and reimbursement.
In some emerging markets, PBMs are emerging as key players in *price negotiation… #
In some emerging markets, PBMs are emerging as key players in *price negotiations* and *drug utilization reviews*.
Practical application #
Engaging PBMs early to understand *utilization management criteria* and align on data sharing agreements.
Challenges #
Limited penetration of PBM models, regulatory restrictions on third‑party administrators, and variability in PBM capabilities.
Health Outcomes Measurement (HOM) – The systematic collection and analysi… #
Health Outcomes Measurement (HOM) – The systematic collection and analysis of data on patient health status, often using standardized instruments such as the EQ‑5D or disease‑specific scales.
HOM data are critical for *value‑based pricing* discussions and for demonstratin… #
HOM data are critical for *value‑based pricing* discussions and for demonstrating *clinical benefit* in payer dossiers.
Practical application #
Implementing *electronic data capture* tools in clinics to gather real‑world outcome metrics.
Challenges #
Ensuring cultural relevance of instruments, training staff in data collection, and integrating outcomes into decision‑making frameworks.
Reimbursement Gap – The difference between the price a manufacturer seeks… #
Reimbursement Gap – The difference between the price a manufacturer seeks for a drug and the amount a payer is willing to reimburse, often leading to delayed market entry.
A significant reimbursement gap may result in a *managed entry agreement* or a *… #
A significant reimbursement gap may result in a *managed entry agreement* or a *price reduction* to bridge the difference.
Practical application #
Conducting *gap analyses* to quantify the shortfall and propose mitigation strategies such as risk‑sharing.
Challenges #
Complex negotiations, potential impact on profitability, and the need to maintain therapeutic value perception.
Health System Financing – The mechanisms through which a health system ra… #
Health System Financing – The mechanisms through which a health system raises and allocates resources to deliver services, including taxes, insurance premiums, and donor funding.
Understanding financing structures is essential for designing *reimbursement pat… #
Understanding financing structures is essential for designing *reimbursement pathways* that align with available funds.
Practical application #
Mapping *revenue streams* to identify potential funding sources for high‑cost therapies.
Challenges #
Fragmented financing, fiscal constraints, and political volatility affecting budget allocations.
Patient‐Centric Access – An approach that prioritizes the needs, preferen… #
Patient‐Centric Access – An approach that prioritizes the needs, preferences, and experiences of patients in the design and implementation of market access strategies.
Incorporating patient input can improve *adherence* and *satisfaction*, leading… #
Incorporating patient input can improve *adherence* and *satisfaction*, leading to better health outcomes and stronger payer arguments.
Practical application #
Conducting *patient focus groups* to gather insights on barriers such as travel distance or out‑of‑pocket costs.
Challenges #
Diverse patient populations, limited representation of marginalized groups, and integrating patient feedback into regulatory processes.
Clinical Trial Site Selection – The strategic choice of locations for con… #
Clinical Trial Site Selection – The strategic choice of locations for conducting clinical studies, taking into account disease prevalence, patient recruitment potential, and regulatory considerations.
Selecting sites in emerging markets can accelerate *patient enrollment* for tria… #
Selecting sites in emerging markets can accelerate *patient enrollment* for trials targeting diseases with high regional burden.
Practical application #
Performing *site feasibility assessments* that evaluate infrastructure, investigator experience, and ethical review capacity.
Challenges #
Variable site quality, logistical constraints, and ensuring data integrity across multiple jurisdictions.
Pricing Transparency – The openness of price information to stakeholders,… #
Pricing Transparency – The openness of price information to stakeholders, facilitating informed decision‑making and reducing information asymmetry.